Research Paper Volume 12, Issue 9 pp 7848—7873
Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma
Figure 11. IC50, CCK8 assay, EdU assay and tube formation assay for anti-tumor effect validation of piperlongumine. (A) IC50 of piperlongumine in normal liver cell line (LO2), HUVEC and HCC cell lines. (B, C) CCK8 assay showed piperlongumine inhibited proliferation of SK-HEP1 (B) and SMMC-7721 (C) cell lines in a dose-dependent manner. (D, E) EdU assay showed the inhibition effect of piperlongumine in proliferation of SK-HEP1 (D) and SMMC-7721 (E) cell lines. (F) Tube formation assay suggested that piperlongumine inhibited angiogenesis via EGF/EGFR axis. (G) Statistical analysis to quantify the inhibitory effect of piperlongumine on angiogenesis.